Conni Bergmann Koury

Contributing Writer

  • All
  • Deals
  • Devices and Diagnostics
  • Digital
  • Genetics
  • Pharma

November 18 2020

Tarsus Closes IPO, Starts Phase IIb/III Trials for Demodex Blepharitis Drop

Late-stage biotech Tarsus Pharmaceuticals raised $88 million in its October NASDAQ debut. In announcing the close of its initial public offering, the company stated that ...
Read More

September 22 2020

Despite Tepid Wall Street Response, Outlook Therapeutics Still Betting on Ophthalmic Bevacizumab Formulation

As Outlook Therapeutics announced top-line results from the first of two registration clinical trials evaluating the safety and efficacy of its formulation of bevacizumab-vikg, ONS-5010, ...
Read More

August 5 2020

Osmotica Will Commercialize and Supply Non-Surgical Droopy Lid Treatment via a Wholly Owned Subsidiary

Last month, the US Food and Drug Administration approved a novel ophthalmic solution to treat acquired blepharoptosis, otherwise known as “droopy lid syndrome.” The solution, ...
Read More
With Positive Phase III Results, Oyster Point Pharma Banks $120 Million from Public Offering

July 1 2020

With Positive Phase III Results, Oyster Point Pharma Banks $120 Million from Public Offering

Oyster Point Pharma has taken two big steps recently to advance development of its OC-01 nasal-spray candidate to treat dry eye disease: the closing of ...
Read More
Has Promising Cannabinoid-Based Drug Development Finally Come to Ophthalmology?

June 3 2020

Has Promising Cannabinoid-Based Drug Development Finally Come to Ophthalmology?

Before Tetra Bio-Pharma's recent announcement of US Food and Drug Administration Orphan Drug Designation for its ophthalmic clinical program, ophthalmology was one of the few ...
Read More